BCMA-CAR-iNKT

N/A

Report date: 2024/06/06 14:45:20

Base Information

Drug NameBCMA-CAR-iNKT
Drug Alias NameAgent-F6-BCMA-CAR-INKTAllo-armored-BCMA-CAR-iNKTMiNK 413 BCMA CAR iNKTMiNK-413
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacementsB-cell maturation protein inhibitors
TargetsB-cell maturation protein
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAgenus Inc
China Registration ClassN/A

Develop Information

Active CompaniesAgenus IncMiNK Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A